Leerink Swann reissued their buy rating on shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) in a research note released on Monday morning.

Several other analysts also recently issued reports on ALXN. Credit Suisse Group AG raised shares of Alexion Pharmaceuticals from a neutral rating to an outperform rating and reduced their price target for the company from $186.00 to $165.00 in a research report on Monday, July 11th. They noted that the move was a valuation call. Royal Bank Of Canada began coverage on Alexion Pharmaceuticals in a research note on Tuesday, July 12th. They set an outperform rating and a $188.00 price objective on the stock. SunTrust Banks Inc. cut their target price on Alexion Pharmaceuticals from $220.00 to $197.00 and set a buy rating on the stock in a research note on Wednesday, July 13th. Jefferies Group reissued a hold rating and issued a $140.00 target price (down from $159.00) on shares of Alexion Pharmaceuticals in a research note on Monday, July 25th. Finally, Stifel Nicolaus lowered their target price on Alexion Pharmaceuticals from $195.00 to $182.00 and set a buy rating on the stock in a report on Friday, July 29th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and sixteen have given a buy rating to the company. Alexion Pharmaceuticals presently has a consensus rating of Buy and an average price target of $173.36.

Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 127.16 on Monday. The company has a market cap of $28.51 billion, a price-to-earnings ratio of 77.54 and a beta of 1.45. The firm has a 50-day moving average of $124.44 and a 200-day moving average of $131.05. Alexion Pharmaceuticals has a 52 week low of $110.56 and a 52 week high of $193.45.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, October 27th. The biopharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.04 by $0.19. The business earned $799 million during the quarter, compared to analyst estimates of $787.07 million. Alexion Pharmaceuticals had a net margin of 12.46% and a return on equity of 10.58%. The firm’s quarterly revenue was up 19.9% on a year-over-year basis. During the same quarter last year, the business earned $1.16 EPS. Equities analysts forecast that Alexion Pharmaceuticals will post $4.64 earnings per share for the current year.

In other news, Director Leonard Bell sold 1,300 shares of the company’s stock in a transaction that occurred on Monday, October 31st. The stock was sold at an average price of $135.28, for a total value of $175,864.00. Following the completion of the sale, the director now directly owns 406,589 shares in the company, valued at $55,003,359.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Julie O’neill sold 650 shares of the company’s stock in a transaction that occurred on Friday, September 2nd. The shares were sold at an average price of $126.29, for a total value of $82,088.50. Following the completion of the sale, the executive vice president now owns 35,384 shares of the company’s stock, valued at $4,468,645.36. The disclosure for this sale can be found here. 4.41% of the stock is owned by insiders.

Several large investors have recently bought and sold shares of the stock. FMR LLC raised its stake in Alexion Pharmaceuticals by 12.0% in the second quarter. FMR LLC now owns 18,745,795 shares of the biopharmaceutical company’s stock worth $2,188,759,000 after buying an additional 2,002,085 shares during the period. BlackRock Investment Management LLC raised its stake in Alexion Pharmaceuticals by 177.0% in the third quarter. BlackRock Investment Management LLC now owns 2,243,677 shares of the biopharmaceutical company’s stock worth $274,940,000 after buying an additional 1,433,769 shares during the period. BlackRock Advisors LLC raised its stake in Alexion Pharmaceuticals by 130.7% in the third quarter. BlackRock Advisors LLC now owns 2,286,891 shares of the biopharmaceutical company’s stock worth $280,236,000 after buying an additional 1,295,520 shares during the period. TIAA CREF Investment Management LLC raised its stake in Alexion Pharmaceuticals by 34.8% in the second quarter. TIAA CREF Investment Management LLC now owns 2,952,205 shares of the biopharmaceutical company’s stock worth $344,699,000 after buying an additional 762,010 shares during the period. Finally, Ameriprise Financial Inc. raised its stake in Alexion Pharmaceuticals by 13.7% in the second quarter. Ameriprise Financial Inc. now owns 6,025,775 shares of the biopharmaceutical company’s stock worth $703,575,000 after buying an additional 728,182 shares during the period. Institutional investors and hedge funds own 96.38% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.